DrJorgeB_George· @DrJorgeBarriuso · X·· 3 天前评分70
正文 · 原文
Nice update of the RASolute 302 at #ESMO26
Looking at the outcomes. Although small numbers, are we facing a roadblock with the KRAS G12R variant?
Represents between 12-15%
Could protein degraders be a viable alternative?
#ESMOAmbassadors @myESMO @GrupoTTD
74 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：DrJorgeB_George · x.com